PCOS Treatment Online: What Telehealth Can (and Can't) Do
PCOS affects 8–13% of women of reproductive age — the most common endocrine disorder in this population — yet the average diagnostic delay still exceeds two years and three clinicians, according to a 2023 international survey of 1,385 women published in Human Reproduction. Telehealth has compressed parts of that timeline: a licensed clinician can now prescribe metformin, spironolactone, combined oral contraceptives, and GLP-1 receptor agonists via async or video consult, without a specialist referral. What telehealth still cannot do is order a transvaginal ultrasound, manage ovulation induction for fertility, or coordinate IVF — those remain in-person. This guide is the practical map: what telehealth can prescribe for PCOS, the labs to bring to the visit, and which platforms in our network are best positioned for the metabolic, dermatologic, and hormonal facets of the syndrome.
What PCOS Actually Is
PCOS is a hormonal and metabolic condition characterised by at least two of three features: irregular or absent ovulation, elevated androgens (testosterone, DHEA-S, or androstenedione), and polycystic ovary morphology on ultrasound. The Rotterdam criteria (2003) remain the standard diagnostic framework. PCOS is not a single disease — it presents across a spectrum from lean PCOS with minimal metabolic disruption to PCOS with significant insulin resistance, weight gain, and cardiovascular risk factors.
What Telehealth Can Prescribe for PCOS
The majority of first-line PCOS medications are within the prescribing scope of a general practitioner or women's health NP — the clinician types most telehealth platforms employ. This means most PCOS management can happen via telehealth without a specialist referral, with the exception of fertility treatment (which requires a reproductive endocrinologist) and surgical intervention.
| Medication | What it treats in PCOS | Available via telehealth? |
|---|---|---|
| Metformin | Insulin resistance, irregular cycles, weight | Yes — most platforms |
| Spironolactone | Hirsutism, acne, androgenic alopecia | Yes — most platforms |
| Combined oral contraceptives | Cycle regulation, acne, hirsutism | Yes — most platforms |
| GLP-1 receptor agonists (semaglutide, tirzepatide) | Weight, insulin resistance, metabolic PCOS | Yes — GLP-1 platforms |
| Progesterone (cyclic) | Cycle regulation, endometrial protection | Yes — women's health platforms |
| Inositol (myo- and D-chiro-) | Insulin sensitivity, ovulation | OTC supplement — no Rx needed |
| Clomiphene / letrozole | Ovulation induction for fertility | Requires specialist (REI) |
| IVF / ART | Fertility treatment | Requires specialist (REI) |
GLP-1s for PCOS: What the Evidence Shows
GLP-1 receptor agonists are not FDA-approved for PCOS, but the off-label clinical case has hardened over the last three years. A 2024 meta-analysis in Diabetes, Obesity and Metabolism (Abdalla et al., 8 RCTs, n=1,124 women with PCOS) reported semaglutide and liraglutide produced 5–10% greater body-weight reduction than metformin alone, with parallel improvements in HOMA-IR, free androgen index, and menstrual regularity. The trial-level threshold that matters clinically is roughly 5%: at that level of weight loss, ovulation typically resumes in previously anovulatory women, and free testosterone falls into the normal range. Tirzepatide data in PCOS specifically are still thin (most published evidence remains in mixed-obesity cohorts), but the mechanistic case is identical and likely stronger given GIP's effect on adipose insulin sensitivity.
Where the GLP-1 case for PCOS is weakest: women with lean PCOS (BMI <25), in whom weight loss is not the lever, and women actively trying to conceive, where the medication must be discontinued before pregnancy.
Inner Balance: A Women's Health Platform Built for Hormonal Complexity
Inner Balance is the only platform in our affiliate network that explicitly positions itself around hormonal complexity in women — including PCOS, postpartum hormone shifts, and perimenopause. Their Oestra® bioidentical HRT protocol and Libida™ libido support are designed for women whose hormonal picture doesn't fit the standard menopause template. For PCOS patients who are also navigating HRT or androgen management, Inner Balance is worth evaluating alongside a GLP-1 platform.
What Telehealth Can't Do for PCOS
- Order a pelvic ultrasound — you'll need to visit a radiology clinic or OB/GYN for ovarian morphology imaging.
- Prescribe ovulation induction medications (clomiphene, letrozole) for fertility — this requires a reproductive endocrinologist.
- Manage IVF or assisted reproduction — specialist only.
- Diagnose PCOS from scratch without labs — you'll need a testosterone panel, LH/FSH ratio, and ideally an ultrasound for a confirmed diagnosis.
Labs to Get Before Your Telehealth PCOS Consult
| Test | Why it matters for PCOS |
|---|---|
| Total testosterone (AM, fasting) | Confirms androgen excess — the core diagnostic criterion |
| Free testosterone or SHBG | Determines bioavailable androgen load |
| DHEA-S | Rules out adrenal androgen excess (adrenal PCOS variant) |
| LH and FSH (day 3 of cycle) | Elevated LH:FSH ratio (>2:1) is a classic PCOS pattern |
| Fasting insulin and glucose (or HbA1c) | Quantifies insulin resistance — guides metformin and GLP-1 decisions |
| TSH | Thyroid disease mimics and co-occurs with PCOS |
| Prolactin | Elevated prolactin causes similar symptoms and must be ruled out |
| AMH (anti-Müllerian hormone) | Elevated in PCOS; also a fertility marker |
Where to Go From Here
Bottom Line
Telehealth can manage 80% of routine PCOS treatment competently — metformin for insulin resistance, spironolactone for hirsutism, OCPs for cycle control, and GLP-1s for the metabolic phenotype. The 20% it can't cover (ultrasound, ovulation induction, IVF) is the part most relevant to women trying to conceive, and that's where telehealth needs to hand off to in-person care. For non-fertility PCOS management — which is most patients, most of the time — a women's health-focused platform like Inner Balance or a metabolic-first platform like Gala Health will outperform a generic GLP-1 storefront because they understand the hormonal context. The provider-pharmacy model matters less here than the clinician's familiarity with PCOS phenotypes.